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Abstract
Background: In 2005, the International Patient Decisions Aid Standards (IPDAS) Collaboration developed quality
criteria for patient decisions aids; one of the quality dimensions dealt with disclosure of conflicts of interest (COIs).
The purposes of this paper are to review newer evidence on dealing with COI in the development of patient
decision aids and to readdress the theoretical justification and definition for this quality dimension.
Methods: The committee conducted a primary systematic literature review to seek published research addressing
the question, “What is the evidence that disclosure of COIs in patient decision aids reduces biased decision
making?” A secondary literature review included a systematic search for recent meta-analyses addressing COIs in
other spheres of health care, including research and publication, medical education, and clinical care.
Results: No direct evidence was found addressing this quality dimension in the primary literature review. The
secondary review yielded a comprehensive Institute of Medicine report, as well as four relevant meta-analyses
addressing disclosure of COIs in health care. They revealed a broad consensus that disclosure of COIs is desirable in
such areas as research publication, guideline development, medical education, and clinical care.
Conclusions: The committee recommends the criteria that are currently used to operationally define the quality
dimension “disclosing conflicts of interest” be changed as follows (changes in italics):
Does the patient decision aid:
• report prominently and in plain language the source of funding to develop or exclusively distribute the patient
decision aid?
• report prominently and in plain language whether funders, authors, or their affiliations, stand to gain or lose by
choices patients make after using the patient decision aid?
Furthermore, based on a consensus that simple disclosure is insufficient to protect users from potentially biased
information, the committee recommends that the IPDAS Collaboration consider adding the following criterion
when the IPDAS consensus process is next conducted: “Does the patient decision aid:
• report that no funding to develop or exclusively distribute the patient decision aid has been received from
commercial, for-profit entities that sell tests or treatments included as options in the patient decision aid?”
Background
Patient decision aids have been defined as tools designed
to help people participate in decision making about health
care options. They provide information on the options
and help patients clarify and communicate the personal
value they associate with different features of the options
[1]. In 2005, the International Patient Decisions Aid Stan-
dards (IPDAS) Collaboration developed quality criteria for
patient decisions aids using a two stage web-based Delphi
process [2]. The process involved 122 representatives of
four stakeholder groups (researchers, practitioners,
patients, and policy makers) from 14 countries, and was
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informed by evidence reviews on each potential quality
dimension. One of the quality dimensions addressed by
this process dealt with disclosure of conflicts of interest
(COIs) in the development and distribution of patient
decision aids.
For the second round of voting in the IPDAS Colla-
boration’s Delphi process, the conceptual definition of
“disclosing conflicts of interest” was for patient decision
aids to be open and honest in stating:
• the funding source for creating and producing patient
decision aids,
• the financial support for practitioners who are
responsible for creating the patient decision aid, and
• the affiliations of patient decision aid developers that
might influence the content of patient decision aids.
In the IPDAS Collaboration’s checklist that eventually
emerged out of the Delphi process, two operational cri-
teria for the disclosing COIs dimension emerged:
Does the patient decision aid:
• report source of funding to develop and distribute
the patient decision aid?
• report whether authors or their affiliations stand to
gain or lose by choices patients make after using the
patient decision aid?
The purposes of this paper are to review newer evidence
on dealing with COIs in the development of patient deci-
sion aids that has emerged since 2005, to readdress the
theoretical justification and definition for this quality
dimension, and to discuss emerging issues that might
cause the original consensus criteria to be rethought.
Theoretical rationale for evaluating patient
decision aids on this quality standard
A definition of “conflict of interest” that is commonly used
by medical journals is, “a set of conditions in which profes-
sional judgment concerning a primary interest (such as
patients’ welfare or the validity of research) tends to be
unduly influenced by a secondary interest (such as finan-
cial gain)” [3]. Practitioners and scientists who read
research reports and reviews in medical journals represent
a relatively well-educated audience, yet journal editors
remain concerned about adequate disclosure of potential
COIs by the authors of those papers [4,5]. Users of patient
decision aids often come from the lay public, and their
ability to detect and evaluate the influence of potential
COIs on the content of the programs they use may be
poorer compared with medical professionals. Thus,
patients may be more vulnerable to any bias incorporated
into patient decision aids than medical professionals are to
biases that may enter into scientific papers in medical jour-
nals. Moreover, patient decision aids may be developed
and disseminated for use by patients or members of the
public without the benefit of scrutiny by independent peer
reviewers or an independent editor, as would generally be
the case for papers in most peer-reviewed medical
journals.
Therefore, it seems reasonable that requirements for dis-
closure of potential COIs should be at least as stringent as
disclosure requirements for medical journals. In addition,
for a lay audience, explaining how the financial interests of
any commercial funders relate to the patient decision aid’s
content seems like a reasonable approach to help patients
and practitioners decide whether a program is likely to be
biased by such interests. While a professional viewer
might know that a particular funder makes or sells a pro-
duct described as an option in the patient decision aid, a
lay viewer might not.
Empirical evidence
Primary literature review
The committee conducted a systematic literature review to
seek published research addressing the question, “What is
the evidence that disclosure of COIs in patient decision
aids reduces biased decision-making?” The PubMed data-
base was searched back ten years from the date of the
search, May 11, 2011. Several preliminary searches were
done to inform the development of a search strategy maxi-
mizing sensitivity at the cost of some specificity. The final
search strategy used the terms: ((shared decision making)
OR (patient centered decision) OR (decision aid) OR
(decision support) AND (disclos* OR (conflict of interest)).
This search yielded 874 titles. The titles were scanned by
at least two committee members, and abstracts or full text
articles as necessary were retrieved for articles flagged as
potentially relevant to the research question by either
reviewer. Ultimately, two articles were judged to be rele-
vant. One (reassuringly) was the original IPDAS paper in
the British Medical Journal describing the development
and validation of the IPDAS quality criteria, including dis-
closure of COIs [2]. The other paper, judged to be only
marginally relevant, was a systematic review of decision
support technologies for the decision about amniocentesis
[6]. While this paper documented that five patient decision
aids on this topic generally included disclosure of potential
COIs, there was no information on the effect of those dis-
closures on the patients’ decisions.
Secondary literature review
Based on this primary literature review, the committee con-
cluded that, as in the IPDAS Collaboration’s original over-
view of the related empirical evidence, there was no direct
evidence to support this quality criterion. The rationale
would need to continue to be based on indirect evidence
on the importance of disclosure of COIs in other spheres
of health care, including research and publication, medical
education, and clinical care. A complete systematic review
of all this evidence was beyond the scope of this project,
but the committee members’ personal bibliographies were
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reviewed for summaries of this evidence, and a search was
conducted on September 29, 2011 going back 5 years for
systematic reviews addressing COIs in medical research
and clinical care. Using the search terms (disclos* OR (con-
flict of interest)) AND systematic review, we identified 1305
titles of which 31 were selected as potentially relevant.
Review of abstracts or full text articles yielded four relevant
systematic reviews. The key new evidence uncovered by the
systematic review and the members’ bibliographies is sum-
marized below.
Reports
A comprehensive report on COIs by the Institute of
Medicine (IOM) of the National Academies in the United
States was identified, which was judged to be a key new
reference supporting the original IPDAS criteria on COI
[7]. In 2009, the IOM of the National Academies in the
United States released a comprehensive report on COIs
in medical research, education, and practice. The com-
mittee summarized the problem as follows: “…financial
ties between medicine and industry may create COIs.
Such conflicts present the risk of undue influence on pro-
fessional judgments and thereby may jeopardize the
integrity of scientific investigations, the objectivity of
medical education, the quality of patient care, and the
public’s trust in medicine.”
The key recommendations of the report included the
following: “The committee recommends that medical
institutions—including academic medical centers, profes-
sional societies, patient advocacy groups, and medical
journals—establish conflict of interest policies that require
disclosure and management of both individual and institu-
tional financial ties to industry.”
The report went on to acknowledge that disclosure was
only the first step in identifying and responding to COIs.
The committee recommended a national reporting pro-
gram accessible to the public disclosing industry payments
to physicians, researchers, health care institutions, profes-
sional societies, patient advocacy groups, and medical edu-
cation providers that would permit verification of
adequate disclosure by patients and the public.
In addition, the report singled out concerns about COIs
in the development of clinical practice guidelines, stating:
“Clinical practice guidelines influence physician practice,
quality measures, and insurance coverage decisions… The
committee recommends that professional societies and
other groups that develop practice guidelines not accept
direct industry funding for guideline development and
generally exclude individuals with COIs from panels that
draft the guidelines. In addition, these groups should make
public their COI policies, their funding sources, and any
financial relationships panel members have with industry.”
This comment is particularly important, as patient deci-
sion aids can be viewed as practice guideline information
for consumption by patients facing health decisions.
Editorials
In his 2006 editorial, Richard Smith pointed out how ubi-
quitous COIs were in health care [4]. He opined about
the evidence that COIs affect the referral of patients and
the interpretations of studies, as well as the importance
of disclosure in health care and the threshold levels of
conflict that might rule out people from referring
patients or writing editorials. In a 2008 editorial, editors
of the Journal of the American Medical Association
wrote, “Primum non nocere does not only hold true for
physicians directly treating patients, but also holds true
for all involved in medical research, biomedical publica-
tion, and medical education [5].”
In fact, by 2008, most medical journals with high impact
factors had author COI policies, although how they were
operationalized varied considerably [8]. Similarly, a survey
of US medical schools in 2007 revealed that most had COI
policies addressing clinical care, though they were rather
weak [9].
Empirical evidence from systematic reviews
Despite the strong opinions expressed in the IOM report
and these editorials, there is relatively limited empirical
evidence on the effect of COI policies on mitigating
negative effects of conflicts of interest on behavior. As
the IOM report summarizes, “Empirical data on conflict
of interest policies are limited, have methodological
shortcomings, and tend to focus on academic institu-
tions.” For example, several studies have shown conflict-
ing results in terms of physicians’ financial disclosures on
patient trust [10,11], demonstrating that how the disclo-
sure is given and interpreted is critical. A recent rando-
mized trial showed that disclosure of research funding
significantly influenced how physicians viewed the meth-
odological quality of the trial and their willingness to
change their practice based on the results [12].
Our search for systematic reviews yielded evidence on
some of these aspects of disclosure. The strongest empiri-
cal evidence on the effect of COIs in medicine comes
from the domain of publication of research findings. A
systematic review that identified 57 drug trials published
between 2002 and 2009 found that trials funded by manu-
facturers yielded more favorable results than in indepen-
dently financed trials; this difference was not explained by
differences in methodological quality between the two
groups of trials [13]. The results of this review were con-
sistent with earlier systematic reviews on this topic; 17 sys-
tematic reviews published between 2003 and 2006 (either
addressing drug trials in general or trials of specific drug
classes, such as antidepressants) found an association
between industry support and published pro-industry
trials, while two did not [14]. However, studies of the
effect of disclosing funding sources for published research
on perceived credibility of the research among practicing
clinicians have yielded mixed results [15,16].
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Another area with empirical evidence supporting the
impact of medical COIs on behavior is the effect of infor-
mation from pharmaceutical companies on clinicians’
prescribing behavior. In a systematic review of studies of
this influence published up to 2008, 38 studies reported
an association between exposure to information from
pharmaceutical companies and lower-quality prescribing
behavior, while 13 did not [17].
Furthermore, Licurse and colleagues conducted a sys-
tematic review of studies of patients’, research partici-
pants’, and journal readers’ attitudes toward financial
disclosure [18]. A search of studies from 1988-2009 found
only 20 relevant articles. Six addressed patients’ reactions
to disclosure of financial ties in clinical care, and five
addressed readers’ reactions to disclosure of financial ties
in research. Ten addressed the importance of disclosing
financial ties in clinical care and research. In clinical care,
patients believed financial ties decreased the quality and
increased the cost of clinical care, and in research, finan-
cial ties affected perceptions of study quality. Most studies
found that the majority of patients and research partici-
pants believed financial ties should be disclosed.
In addition to these systematic reviews, a recent narra-
tive review cited evidence that financial relationships with
referral sources, health insurers, and the drug and device
industries can bias physician decision making [19].
Discussion
In summary, based on the IOM report and the data from
the systematic reviews on this topic, there is a broad con-
sensus in medicine that disclosure of COIs is desirable in
such areas as research publication, guideline development,
medical education, and clinical care. Moreover, people—
whether as patients or research subjects—generally feel
financial ties between clinicians or researchers and indus-
try should be disclosed. Patient decision aids are designed
to provide patients with unbiased information about their
options and the pros and cons of those options to help
them work with their clinicians to make informed, value-
based decisions for their personal health care. The poten-
tial for bias in patient decision aids due to COIs seems as
great as in these other areas of health care. Moreover, the
phenomenon of patients making suboptimal decisions
based on biased information might have even more drastic
consequences, particularly for “high stakes” decisions
about diagnosis and treatment of serious medical condi-
tions. Therefore, despite the lack of direct evidence per-
taining to patient decision aids, the committee strongly
felt that it remains important to require disclosure of
potential COIs as a quality criterion, both in terms of
funding for the development of patient decision aids, as
well as funding for the authors responsible for the content
of the aids. To make these disclosures useful, however, the
committee judged that the operational definitions of this
quality dimension—as reflected in the two current assess-
ment criteria—be modified slightly. The committee judged
that these criteria should not be considered met unless
users could readily find the disclosure information and be
likely to interpret it correctly. Therefore, the committee
recommended that disclosure information in patient deci-
sion aids be provided prominently and in plain language.
By “prominently”, the committee means that disclosure
information should be provided along with the body of
clinical information in the decision aid and not separately
—say, on a separate web site or in a separate technical
document. Disclosure information should be presented
in a similar font to clinical information and not in the
“fine print,” whether the decision aid is provided in
paper, video, or Internet-based format.
By “plain language”, the committee means that the
disclosure information should be provided in simple,
straightforward language and not in technical jargon
that would be difficult for lay users to comprehend.
The committee has also clarified the language around
the declaration of sources of funding for decision aid dis-
tribution. Once produced, a patient decision aid may be
sold or licensed for use to many different entities, and
declaring all such relationships would be impractical.
However, when a patient decision aid is produced for
exclusive distribution by one funder, even if that funder
does not pay for the development, that funding should be
disclosed.
Going further, committee members were uncomforta-
ble, even in the absence of direct evidence addressing this
quality dimension, that simple disclosure is sufficient to
protect lay viewers from potentially biased information in
patient decision aids. Lay viewers may not appreciate, to
the same degree that health care professionals might, the
potential for bias when commercial, for-profit entities
provide funding for patient decision aids that discuss
their own products. This discomfort on the part of the
committee parallels a growing sense in the literature [20],
particularly as reflected in the recent comprehensive
IOM report [7], that disclosure is necessary but not suffi-
cient to avoid bias in research publication, guideline
development, medical education, and clinical care.
Based on the interim review of the evidence, the com-
mittee decided to recommend to the IPDAS Collaboration
that the assessment criteria for this quality dimension be
extended with the addition of a third criterion. The com-
mittee felt that disclosure alone is not sufficient to protect
lay users from potential bias resulting from funding of
patient decision aids by commercial, for-profit entities that
produce or distribute tests or treatments included as
options. This third quality criterion would not be awarded
unless the disclosure information provided revealed that
the patient decision aid’s developers had received no fund-
ing from commercial, for-profit entities that produce or
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distribute tests or treatments included as options in the
patient decision aid.
Further research is clearly necessary, especially research
applying directly to the relationship between funding
sources and biases in patient decision aids. This work
will need to include fundamental methodological studies
of how bias in patient decision aids can be accurately and
reliably judged. In addition, more research is needed on
the necessary level of detail and prominence of disclosure
statements in patient decision aids, particularly in multi-
media presentations, as well as how viewers interpret
them. The IPDAS Collaboration’s promotion of routine
disclosure of potential COIs in patient decision aid devel-
opment can help facilitate this research.
Conclusion
Based on a review of the evidence, the committee recom-
mends the criteria which represent the operational defini-
tion of the disclosure of conflict of interest quality
dimension be changed as follows (change in italics): Does
the patient decision aid:
• report prominently and in plain language the source
of funding to develop or exclusively distribute the
patient decision aid?
• report prominently and in plain language whether
funders, authors or their affiliations stand to gain or
lose by choices patients make after using the patient
decision aid?
Furthermore, based on a consensus that simple disclo-
sure is insufficient to protect users from potentially biased
information, the committee recommends that the IPDAS
Steering Committee consider adding the following criter-
ion when the IPDAS consensus process is next conducted:
“Does the patient decision aid:
• report that no funding to develop or exclusively distri-
bute the patient decision aid has been received from com-
mercial, for-profit entities that sell tests or treatments
included as options in the patient decision aid?”
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